FinnGen data analysis environment, FinnGen Sandbox, is now one of the few certified secure operating environments in Finland. The certificate was granted on 20th April 2022 and is valid for five years.

We are happy to announce that the FinnGen data freeze 7 results and summary statistics are now publicly available!

We are pleased to announce that the FinnGen data freeze 6 results and summary statistics are now publicly available!

The public examination of the first FinnGen-based doctoral dissertation took place in October, 2021. Warm congratulations to Satu Strausz!

Boehringer Ingelheim has joined FinnGen, a large-scale academic – industry, genome research collaboration in Finland aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants.

The first sub-project of the FinnGen study to invite participants for further clinical examinations will begin in eastern Finland. The project will explore methods that are suitable for investigating the progression of Alzheimer's disease and other, less severe memory disorders. The aim is to improve early diagnostics of Alzheimer's disease and to increase understanding of its pathogenesis.

Open Targets is an innovative, large-scale public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. We are pleased to announce that the publicly available FinnGen results have now been integrated into the brand new version 5 of the Open Targets Genetics Portal!

We are excited to announce that the FinnGen data freeze 5 results and summary statistics are now publicly available!